BRIEF-AstraZeneca Says Enhertu Reduced Risk Of Disease Progression By 72% Vs T-DM1

AstraZeneca PLC: * ASTRAZENECA PLC - ENHERTU REDUCED RISK OF DISEASE PROGRESSION BY 72%

* ASTRAZENECA - IN KEY SECONDARY ENDPOINT OF PFS ASSESSED BY INVESTIGATORS, PATIENTS TREATED WITH ENHERTU EXPERIENCED A THREE-FOLD IMPROVEMENT IN PFS * ASTRAZENECA - IN KEY SECONDARY ENDPOINT OF PFS ASSESSED BY INVESTIGATORS, PATIENTS TREATED WITH ENHERTU EXPERIENCED A THREE-FOLD IMPROVEMENT IN PFS

* ASTRAZENECA - CONFIRMED OBJECTIVE RESPONSE RATE (ORR) MORE THAN DOUBLED IN ENHERTU ARM VERSUS T-DM1 ARM * ASTRAZENECA: ENHERTU REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 72% VERSUS. TRASTUZUMAB EMTANSINE (T-DM1) IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)